# FDA/NIH Clinical Trial Protocol Template

## Template Version Information

- **Template Source:** FDA Guidance for Industry: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies
- **NIH Reference:** NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information
- **ICH Reference:** ICH E6(R2) Good Clinical Practice
- **Last Updated:** 2024

---

## Protocol Structure Overview

This template provides the standard 12-section structure for clinical trial protocols:

| Section | Title | Content Focus |
|---------|-------|---------------|
| 1 | Statement of Compliance | Regulatory and ethical compliance |
| 2 | Protocol Summary | Study synopsis and key parameters |
| 3 | Introduction | Background, rationale, benefit-risk |
| 4 | Objectives and Endpoints | Study objectives and measurable endpoints |
| 5 | Study Design | Overall design, randomization, blinding |
| 6 | Study Population | Inclusion/exclusion criteria |
| 7 | Study Intervention | Treatment administration and handling |
| 8 | Discontinuation/Withdrawal | Stopping rules and procedures |
| 9 | Study Assessments | Efficacy, safety, laboratory procedures |
| 10 | Statistical Considerations | Sample size, analysis plan |
| 11 | Supporting Documentation | Regulatory, ethical, operational |
| 12 | References | Literature and regulatory citations |

---

## Section Templates

### Title Page Template

```
[INSTITUTION/SPONSOR LOGO]

CLINICAL STUDY PROTOCOL

Protocol Title: [Full descriptive title]

Protocol Number: [Unique identifier]
IND/IDE Number: [If applicable]

Version: [X.X]
Date: [DD-MMM-YYYY]

Sponsor: [Organization name]
         [Address]
         [Contact information]

Medical Monitor: [Name, MD]
                 [Contact information]

CONFIDENTIAL

This document contains confidential information belonging to [Sponsor].
Do not copy or distribute without authorization.
```

---

### Section 1: Statement of Compliance

```markdown
# 1. STATEMENT OF COMPLIANCE

## 1.1 Protocol Compliance

This clinical study will be conducted in accordance with this protocol.
No changes to the protocol will be implemented without prior written
approval from the Sponsor except when necessary to eliminate an
immediate hazard to study participants.

## 1.2 Regulatory Compliance

This study will be conducted in compliance with:

- [For US Studies]
  - Title 21 Code of Federal Regulations (CFR) Parts 50, 54, 56, 312 (drugs) or 812 (devices)
  - Health Insurance Portability and Accountability Act (HIPAA)

- [For International Studies]
  - International Conference on Harmonisation (ICH) E6(R2) Good Clinical Practice
  - Declaration of Helsinki (current version)
  - Applicable local regulations

## 1.3 Institutional Review Board/Ethics Committee

The protocol and informed consent form will be reviewed and approved by
the IRB/Ethics Committee at each participating site before study initiation.
Any protocol amendments will be submitted for IRB/EC approval.
```

---

### Section 2: Protocol Summary (Synopsis)

```markdown
# 2. PROTOCOL SUMMARY

## 2.1 Synopsis

| Parameter | Description |
|-----------|-------------|
| **Protocol Title** | [Title] |
| **Protocol Number** | [Number] |
| **Phase** | [Phase 1/2/3/4] |
| **Study Population** | [Brief description] |
| **Sample Size** | [N subjects] |
| **Study Design** | [e.g., Randomized, double-blind, placebo-controlled] |
| **Study Duration** | [Duration per subject] |
| **Primary Objective** | [Objective] |
| **Primary Endpoint** | [Endpoint with timepoint] |
| **Investigational Product** | [Name and description] |
| **Dosage and Administration** | [Dose, route, frequency] |
| **Comparator** | [Placebo/active comparator/none] |

## 2.2 Study Schema

[Insert study design diagram showing:
- Screening period
- Treatment period(s)
- Follow-up period
- Key assessments
- Randomization point]
```

---

### Section 3: Introduction

```markdown
# 3. INTRODUCTION

## 3.1 Background

[Provide background on:
- Disease/condition being studied
- Current treatment landscape
- Unmet medical need
- Investigational product overview]

## 3.2 Rationale for the Study

[Explain:
- Why this study is being conducted
- Scientific rationale for the intervention
- Rationale for the study design
- Rationale for the dose/regimen selected]

## 3.3 Risk/Benefit Assessment

### 3.3.1 Known Potential Risks

[List known risks from:
- Preclinical studies
- Prior clinical experience
- Class effects]

### 3.3.2 Known Potential Benefits

[Describe potential benefits:
- Direct therapeutic benefit
- Contribution to scientific knowledge]

### 3.3.3 Assessment of Benefit-Risk Balance

[Provide overall assessment justifying why benefits outweigh risks]
```

---

### Section 4: Objectives and Endpoints

```markdown
# 4. OBJECTIVES AND ENDPOINTS

## 4.1 Primary Objective

[State the primary objective in terms of what the study aims to demonstrate]

## 4.2 Secondary Objectives

1. [Secondary objective 1]
2. [Secondary objective 2]
3. [Secondary objective 3]

## 4.3 Exploratory Objectives

1. [Exploratory objective 1]
2. [Exploratory objective 2]

## 4.4 Endpoints

### 4.4.1 Primary Endpoint

| Endpoint | Definition | Timepoint |
|----------|------------|-----------|
| [Name] | [Precise definition] | [When measured] |

### 4.4.2 Secondary Endpoints

| Endpoint | Definition | Timepoint |
|----------|------------|-----------|
| [Name 1] | [Definition] | [Timepoint] |
| [Name 2] | [Definition] | [Timepoint] |

### 4.4.3 Exploratory Endpoints

| Endpoint | Definition | Timepoint |
|----------|------------|-----------|
| [Name 1] | [Definition] | [Timepoint] |
```

---

### Section 5: Study Design

```markdown
# 5. STUDY DESIGN

## 5.1 Overall Design

[Describe the overall study design including:
- Study type (interventional/observational)
- Allocation (randomized/non-randomized)
- Intervention model (parallel/crossover/single group)
- Masking (open/single-blind/double-blind)
- Primary purpose (treatment/prevention/diagnostic)]

## 5.2 Scientific Rationale for Study Design

[Explain why this design was chosen:
- Appropriateness for the research question
- Control of bias
- Feasibility considerations]

## 5.3 Justification for Dose Selection

[Provide rationale for:
- Dose levels selected
- Dosing frequency
- Treatment duration
- Dose modifications (if applicable)]

## 5.4 End of Study Definition

The end of the study is defined as:
- [Last subject's last visit, OR]
- [Database lock, OR]
- [Other milestone]
```

---

### Section 6: Study Population

```markdown
# 6. STUDY POPULATION

## 6.1 Inclusion Criteria

Subjects must meet ALL of the following criteria:

1. Age ≥ [X] years and ≤ [Y] years
2. [Diagnosis criterion]
3. [Disease severity criterion]
4. [Laboratory criterion]
5. [Informed consent criterion]
6. [Contraception criterion if applicable]
7. [Other criteria...]

## 6.2 Exclusion Criteria

Subjects meeting ANY of the following criteria will be excluded:

1. [Prior treatment exclusion]
2. [Concomitant condition exclusion]
3. [Laboratory exclusion]
4. [Pregnancy/lactation]
5. [Known allergy/hypersensitivity]
6. [Participation in other studies]
7. [Other exclusions...]

## 6.3 Lifestyle Considerations

### 6.3.1 Meals and Dietary Restrictions
[Any dietary requirements]

### 6.3.2 Caffeine, Alcohol, and Tobacco
[Any restrictions]

### 6.3.3 Activity
[Any activity restrictions]

## 6.4 Screen Failures

Screen failures are defined as subjects who consent but do not meet
eligibility criteria. [Describe re-screening policy]

## 6.5 Strategies for Recruitment and Retention

[Describe recruitment strategies and retention measures]
```

---

### Section 7-12 Templates

[Templates for Sections 7-12 follow the same structured format,
covering Study Intervention, Discontinuation, Assessments,
Statistics, Operations, and References]

---

## Abbreviations List

| Abbreviation | Definition |
|--------------|------------|
| AE | Adverse Event |
| CFR | Code of Federal Regulations |
| CRF | Case Report Form |
| DSMB | Data Safety Monitoring Board |
| EC | Ethics Committee |
| GCP | Good Clinical Practice |
| ICF | Informed Consent Form |
| ICH | International Council for Harmonisation |
| IDE | Investigational Device Exemption |
| IND | Investigational New Drug |
| IRB | Institutional Review Board |
| ITT | Intent-to-Treat |
| LOCF | Last Observation Carried Forward |
| PP | Per Protocol |
| SAE | Serious Adverse Event |
| SAP | Statistical Analysis Plan |

---

## Document History

| Version | Date | Author | Description of Changes |
|---------|------|--------|------------------------|
| 1.0 | [Date] | [Author] | Original version |

---

*This template is provided as guidance. Customize for your specific study requirements.*
